FDA OKs Updated Moderna and Pfizer-BioNTech COVID-19 Vaccines
The FDA has approved and authorized updated Moderna and Pfizer-BioNTech COVID-19 vaccines for the 2024-2025 season, designed to target current variants.
Tag: Pfizer
All
Latest
All
Latest
FDA Approves Updated COVID Vaccines from Pfizer and Moderna
The mRNA vaccines are formulated to more closely target currently circulating variants by including a monovalent component that corresponds to the Omicron variant XBB.1.5.
All
Latest
Five RSV Articles for the Week
FDA panel favors approval for two RSV vaccines, 'Tripledemic' hits US households, and a monoclonal antibody may be ready for next season—here are five RSV stories you should check out this week.
FDA Authorizes Moderna, Pfizer Vaccines for Children as Young as 6 Months Old
The FDA authorized emergency use of the Moderna COVID-19 Vaccine and the Pfizer-BioNTech COVID-19 Vaccine for the prevention of COVID-19 for in children as young as 6 months old.Â
Read More
FDA Advisory Panel Recommends Moderna, Pfizer Vaccines for Children 6-months and Older
The FDA’s Vaccine and Related Biological Products Advisory Committee voted unanimously in favor of authorizing the Moderna and Pfizer/BioNTech COVID-19 vaccines for children as young as 6-months old.
Read More
FDA Expands Authorization of Pfizer COVID Booster to Kids 5-through-11
Children age 5-through-11 are now authorized to receive the Pfizer COVID booster at least five months after completion of their primary two-dose series of the Pfizer vaccine.
Read More
Pfizer-BioNTech Vaccine Study Looks at Healthcare Cost-Savings
The health and economic impact of the Pfizer-BioNTech vaccine during its first year of rollout in the US is described in a new study in the peer-reviewed Journal of Medical Economics.
Read More
What is Paxlovid and How Will it Help the Fight Against Coronavirus?
An oral antiviral, Paxlovid has proved successful at reducing the chances of hospitalization among COVID-19 sufferers, but has suffered from a slow rollout to pharmacies.
Read More
Pfizer Submits Pediatric COVID Booster for Authorization
Pfizer Inc and BioNTech SE have submitted an application for US FDA authorization of a 10-µg booster dose of its pediatric COVID booster for children age 5 through 11 years old.Â
Read More
Pfizer/BioNTech Request FDA OK of Second Booster Dose for Seniors
Pfizer and BioNTech have requested FDA authorization of a second booster dose of their COVID-19 vaccine for adults 65 years of age and older.
Read More
Third Vaccine Dose Effectiveness Wanes After Four Months
A nationwide study from the U.S. Centers for Disease Control and Prevention shows that immunity against severe COVID-19 disease begins to wane four months after receipt of the third dose of an mRNA vaccine.
Read More
FDA Delays Meeting on Pfizer Vaccine for Children 6-months to Age 5
The FDA has postponed a Feb 15 meeting of its Vaccines and Related Biological Products Advisory Committee that was intended to discuss emergency use authorization of a two-dose regimen of the Pfizer-BioNTech vaccine for children age 6-months through 4-years-old.
Read More
Pfizer Vaccine Submitted for Children 6-months through 4-Years-Old
Pfizer and BioNTech have submitted an application for emergency authorization of its COVID-19 vaccine in children age 6 months through 4 years old.
Read MoreFDA Authorizes Pfizer Booster for Children Age 12-15
The Pfizer and BioNTech COVID-19 vaccine is the first to be FDA-authorized as a booster for adolescents 12 through 15 years of age in the US.
Read More
Pfizer Paxlovid COVID Antiviral Pill Authorized by FDA
The US FDA has authorized the emergency use of Paxlovid (nirmatrelvir tablets and ritonavir tablets) for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients age 12 and older.
Read More